Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report)’s share price gapped up before the market opened on Friday. The stock had previously closed at $3.32, but opened at $3.5697. Raia Drogasil shares last traded at $3.5697, with a volume of 33,444 shares.
Raia Drogasil Trading Up 6.7%
The firm has a market capitalization of $4.70 billion and a price-to-earnings ratio of 71.39. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.41 and a quick ratio of 0.58. The business’s 50-day moving average price is $3.67 and its 200 day moving average price is $3.89.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. Raia Drogasil had a return on equity of 18.20% and a net margin of 2.97%.The firm had revenue of $2.17 billion during the quarter, compared to analyst estimates of $2.32 billion. On average, equities analysts forecast that Raia Drogasil S.A. will post 0.17 earnings per share for the current fiscal year.
About Raia Drogasil
Raia Drogasil SA, known as RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a nationwide network of drugstores under the Raia and Drogasil brands, offering prescription medicines, over-the-counter products, vitamins, personal-care items, cosmetics and other health-related merchandise.
The company also provides digital shopping and delivery services through its online channels, supporting customers with prescription fulfillment and access to pharmacy products.
Featured Stories
- Five stocks we like better than Raia Drogasil
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
- Target’s Holiday Blitz: Slashing Prices to Capture Market Share
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
